Subrenal Capsule PDX Models (PDX-SRC)

Subrenal capsule implantation places tumor tissue beneath the fibrous capsule of the kidney, one of the most densely vascularized sites available in the mouse. The site addresses a specific problem: tumor types that engraft poorly or not at all at subcutaneous sites, where a failed take rate would otherwise make patient-derived modeling impossible.

The mechanism is vascular. Tissue implanted subcutaneously must survive an initial avascular period before host vessels reach it, and poorly tolerant material is lost during that interval. The subrenal capsule site delivers rapid perfusion, shortening the ischemic window and markedly improving establishment for refractory material. Published work reports substantially improved establishment at this site for difficult tumor types including non-small cell lung cancer and prostate cancer.

Altogen Labs performs subrenal capsule implantation as a survival surgical procedure in an IACUC-regulated facility. Where a program has failed to establish a model subcutaneously, this is usually the next step worth taking before concluding that a tumor type cannot be modeled. To discuss feasibility, request a quote.

Applications

The site is appropriate where the alternative is no model at all. Typical indications include tumor types with low subcutaneous establishment rates, limited biopsy material where a single attempt must succeed, and early passage establishment of a patient-derived line that will subsequently be transferred to a conventional site for pharmacology.

It is also used for short-term primary tumor tissue response assays, in which fresh patient material is implanted, exposed to test agents, and assessed histologically within a compressed timeframe, before the stromal replacement associated with serial passage has occurred. This preserves the human stromal component that is lost over successive passages at any site.

Practical constraints

Three constraints determine whether this site suits a given program, and all three should be settled before a study is designed around it.

The procedure is technically demanding. Implantation requires survival surgery, exposure of the kidney, and careful placement of a small tissue fragment beneath the capsule without capsular rupture or renal injury. Operator experience materially affects outcome, which is why this is not a site to attempt occasionally.

Tumor volume is limited by the anatomy of the site. The subrenal capsule cannot accommodate the tumor burden achievable subcutaneously, which constrains the dynamic range available for efficacy endpoints and rules out long growth studies.

Caliper measurement is impossible. Longitudinal assessment requires imaging, or the study is designed around staged terminal cohorts with tumor weight and histological assessment as endpoints.

Study design

Because of the volume constraint, subrenal capsule studies are typically designed either as establishment studies, where the objective is a viable line for transfer, or as short duration response studies with histological and molecular endpoints rather than volumetric ones. Endpoints commonly include terminal tumor weight, proliferation and apoptosis indices by immunohistochemistry, histological assessment of viable tumor fraction, and molecular readouts of target engagement.

Applied examples

Rescue of a failed establishment attempt. A prostate tumor that did not establish subcutaneously across two attempts is implanted subrenally, establishes, and is then transferred to a subcutaneous site at second passage for a conventional efficacy study.

Short-term response assay. Fresh tumor tissue is implanted and treated for a compressed period, with viable tumor fraction and proliferation index compared against vehicle at termination, providing a response signal while the human stromal component is still present.

Scarce biopsy material. A single small core biopsy, insufficient for parallel subcutaneous implantation across a cohort, is implanted subrenally to maximize the probability that one attempt succeeds.

Surgical conduct and documentation

All procedures are conducted under active IACUC protocols. Because implantation is a survival surgery at an internal site, the protocol specifies anesthesia, analgesia, surgical technique, postoperative monitoring frequency, and renal function related humane endpoints in addition to tumor burden endpoints. Passage history, host background, implantation site, and provenance are recorded consistent with established reporting standards for patient-derived xenografts. GLP standards are applied where a study is formally designated as GLP.

Send tumor type and tissue availability, or request a quote.